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Abstract
The in vitro activity of cefoxitin and imipenem was compared for
43 strains of the Mycobacterium abscessus complex, mostly isolated
from cystic ﬁbrosis patients. The MICs of imipenem were lower
than those of cefoxitin, although the number of imipenem-
resistant strains was higher according to the CLSI breakpoints.
Strain comparisons indicated that the MICs of cefoxitin were
signiﬁcantly higher for Mycobacterium bolletii than for M. abscessus.
The MICs of both b-lactams were higher for the rough morpho-
type than for the smooth morphotype. The clinical impact of the
in vitro difference between the activity of imipenem and that of
cefoxitin remains to be determined.
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Mycobacterium abscessus is the rapidly growing mycobacterium
most frequently recovered from pulmonary infections, partic-
ularly in cystic ﬁbrosis patients [1,2]. M. abscessus is known to
be one of the most drug-resistant mycobacteria, and the
optimal treatment of lung disease, including its duration, has
not yet been formally established [3,4].
Clinical isolates of M. abscessus have been assigned to three
species on the basis of the rpoB sequence: M. abscessus sensu
stricto, Mycobacterium bolletii, and Mycobacterium massiliense
[5,6]. Recently, M. massiliense and M. bolletii have been united
and reclassiﬁed as M. abscessus ssp. bolletii comb. nov. [7].
However, the distinction between M. bolletii and M. massiliense
is clinically relevant, as an erm gene confers inducible resistance
to macrolides in M. bolletii (and M. abscessus) but not in
M. massiliense [8,9]. In clinical studies, rates of response to
clarithromycin-based antibiotic combinations were signiﬁcantly
higher in pulmonary infections caused by M. massiliense than in
those caused by M. abscessus [10,11]. Thus, expression of the
erm gene further limits the therapeutic options for M. absces-
sus and M. bolletii infections. On the basis of limited clinical
evidence, many cystic ﬁbrosis centres have abandoned clari-
thromycin, and use two parenteral agents: an intravenous b-
lactam, either imipenem or cefoxitin, combined with amikacin
[3,12].
The in vitro activity of cefoxitin and imipenem has been
previously evaluated [11], but the three species of the
M. abscessus complex have not been extensively compared.
In the present study, we determined the MICs and MBCs of
cefoxitin and imipenem for 43 unrelated clinical strains of the
M. abscessus complex, mostly isolated from cystic ﬁbrosis
patients, and characterized by multilocus sequence typing. We
also evaluated the impact of colony morphotype, growth phase
and culture medium on the activity of these b-lactams.
The 43 clinical isolates of M. abscessus were previously
collected from 12 French hospitals and one German hospital
between 1997 and 2008 [13]. Multilocus sequence typing
showed that these isolates are unrelated, and include repre-
sentatives of the M. abscessus complex (15 M. abscessus, 14
M. bolletii, and 14 M. massiliense) [13]. Forty-two strains were
isolated from respiratory secretions from 41 cystic ﬁbrosis
patients, who met the diagnostic criteria for non-tuberculous
mycobacterial respiratory disease [3], and from one human
immunodeﬁciency virus patient. The remaining isolate was
recovered from synovial ﬂuid. The reference strains M. absces-
sus CIP 104536T, M. bolletii CIP 108541T, M. massiliense
CIP 108297T and Staphylococcus aureus CIP 4.83 were used
as controls.
Susceptibility testing of cefoxitin (Panpharma, Fougeres,
France) and imipenem (MSD, Courbevoie, France) was
performed according to the CLSI guidelines [14], except that
resazurin was used to facilitate reading. Brieﬂy, the broth
microdilution method was performed in cation-adjusted
Mueller–Hinton Broth (CAMHB) with an inoculum of
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ca. 5 9 105 CFU/mL in the exponential phase of growth. After
3 days of incubation at 30°C, 5 lL of a 0.025% (w/v) resazurin
solution (Sigma-Aldrich, Saint-Quentin Fallavier, France) was
added to each well (100 lL), and incubation was continued for
24 h at 30°C [15]. Middlebrook 7H9 (BD-Difco, Le Pont de
Claix, France) broth supplemented with 10% (v/v) oleic acid,
dextrose and catalase (BD-Difco) and 0.05% (v/v) Tween-80
(Sigma-Aldrich; 7H9c medium) was tested in the same condi-
tions, except that resazurin was added after 2 days of
incubation. MBCs were determined by plating 100 lL of a
1:10 dilution from each well onto Brain Heart Infusion agar
plates. Plates were incubated at 30°C for 7 days, and the MBC
was deﬁned as the lowest antibiotic concentration that reduced
bacterial counts by at least 99.9% in comparison with the
inoculum. Reference strains were included in each plate as
controls (data presented in Table S1).
In CAMHB, MICs of cefoxitin were signiﬁcantly higher for
M. bolletii than for M. abscessus (p 0.006; Mann–Whitney U-
test; Table 1), whereas no difference was observed between
M. bolletii and M. massiliense (p 0.13) or between M. abscessus
and M. massiliense (p 0.46). Imipenem was similarly active
against the three species (p 0.20, Kruskall–Wallis test). MICs
of imipenem were lower than those of cefoxitin for the three
species (p <104, Mann–Whitney U-test), but more isolates
were resistant to imipenem than to cefoxitin according to
CLSI breakpoints [14] (Table 1). Susceptibilities to imipenem
and cefoxitin were correlated with a Pearson correlation
coefﬁcient of 0.74 (Fig. S1), implying that strains with a high
cefoxitin MIC were likely to have a high imipenem MIC. The
addition of 4 mg/L clavulanate (kindly provided by GSK,
Marly-le-Roi, France) did not change the MIC values.
According to CLSI breakpoints [14], all M. abscessus and
M. massiliense isolates were susceptible or intermediately
resistant to cefoxitin (Table 1). One M. bolletii isolate was
resistant to this drug. Two M. abscessus, one M. bolletii and
four M. massiliense isolates were resistant to imipenem.
Imipenem resistance rates of 19% and 48% have been
previously reported for M. abscessus and M. massiliense,
respectively [11].
Clinical isolates of M. abscessus show a smooth or rough
colony morphotype, owing to the loss of glycopeptidolipid
production by the latter variants [16]. In humans, smooth
variants of M. abscessus are found at early stages of the
infection, whereas rough variants generally appear several
years later, and the morphological switch has been linked to
clinical deterioration [17]. MICs of cefoxitin and imipenem
were higher for the rough morphotype than for the smooth
morphotype (p 0.022 and p 0.004, respectively, Mann–Whit-
ney U-test). The cefoxitin-resistant strain of M. bolletii showed
a rough morphotype (Table 1). It remains to be determined
whether this difference directly reﬂects a loss of glycopeptid-
olipid production or, alternatively, results from target mod-
iﬁcations associated with prolonged exposure of rough
isolates to the antibiotic selective pressure during chronic
infection.
The MBCs of cefoxitin and imipenem were determined in
the exponential and stationary phases of growth (Table S2).
The MBC50 values were found to be one or two dilutions
higher than the MICs in exponentially growing bacteria
(Table S2). Neither cefoxitin nor imipenem was bactericidal
in the stationary phase (MBC >256 mg/L).
MICs of the two b-lactams were lower for 7H9c than for
CAMHB (p <104, Mann–Whitney U-test), and the difference
was more pronounced for imipenem than for cefoxitine
(Table 2). The MIC ranges were narrower in 7H9c than in
CAMHB. 7H9c is commonly used for the growth of myco-
bacteria, as it allows greater ease of handling and the use of
more uniform inocula. However, this medium cannot be
TABLE 1. MICs (mg/L) of cefoxitin (FOX) and imipenem (IPM) determined in cation-adjusted Mueller–Hinton broth for 43
clinical isolates of Mycobacterium abscessus complex
Drug Clinical isolates (no. of strains)
No. of strains with indicated MIC
MIC50 MIC90 R (%)≤4 8 16 32 64 128
FOX All (43) 8 28 6 1 32 64 2
M. abscessus (15) 4 11 32 32 0
M. bolletii (14) 10 3 1 32 64 7
M. massiliense (14) 4 7 3 32 64 0
Smooth (25) 6 18 1 32 32 0
Rough (18) 2 10 5 1 32 64 6
IPM All (43) 1 11 25 5 1 16 32 14
M. abscessus (15) 6 7 2 16 32 13
M. bolletii (14) 3 10 1 16 16 7
M. massiliense (14) 1 2 8 3 16 32 21
Smooth (25) 1 9 14 1 16 16 4
Rough (18) 2 11 4 1 16 32 28
Italic and bold type indicate susceptible and resistant categories, respectively, of interpretive criteria for each antimicrobial agent according to the 2011 CLSI breakpoints [14].
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recommended, as membrane permeability appears to be
affected in this medium, presumably because of Tween-80, as
previously discussed [18,19].
In conclusion, in the recommended medium (CAMHB),
most of the isolates are moderately susceptible to cefoxitin
and imipenem. According to the CLSI breakpoints, the number
of resistant isolates for the three species of the M. abscessus
complex was higher for imipenem than for cefoxitin, in spite of
lower MICs and MBCs. Moreover, pharmacokinetic parame-
ters are more favourable for cefoxitin used at 12–16 g daily, as
recommended for M. abscessus infections, than for imipenem
(500 mg two to four times daily) [3,20]. The clinical impact of
this in vitro difference in susceptibility between imipenem and
cefoxitin remains to be determined. As the MIC distributions
for cefoxitin and imipenem are very close to the breakpoints,
epidemiological cut-off values for wild-type strains should be
determined to improve the interpretation of MICs for clinical
strains.
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